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Abstract 
CDC25A phosphatase is essential for cell cycle 
progression by activating the cyclin-associated 
kinases CDK4/6, CDK2 and CDK1. Its invalidation 
in mice is embryonic lethal. Its expression is tigthtly 
regulated at many levels and its overexpression is 
observed in various cancers, often associated with 
high grade tumors and poor prognosis. 
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Identity 
HGNC (Hugo): CDC25A 
Location: 3p21.31 
Other names: CDC25A2 
Local order 
The gene is located telomeric to CAMP (cathelicidin 
antimicrobial peptide) and centromeric to 
LOC729349 (a pseudogene similar to 60S ribosomal 
protein L17 (L23)). The gene starts at 48,173,672 bp 
from pter and ends at 48,204,805 bp from pter with 
a total size of 31,133 bases. 
DNA/RNA 
Description 
CDC25A is about 31.13 Kb located on the short (p) 
arm of chromosome 3, in the centromere-to-telomere 
orientation. The gene has 15 exons and the start 
codon is located at the end of exon 1 and stop codon 
in the beginning of exon 15. 
Genomic organization of human CDC25A gene on chromosome 3 p-ter. 
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Domains of different isoforms of CDC25A (A1 and A2). The splice variant A2 lacks an in-frame exon (exon 6) encoding 40 amino 
acids (amino acid 160-201), however, has the same N- and C-termini compared to isoform A1. The approx. molecular weight of 
each isoform is mentioned in parenthesis. 
 
Transcription 
The CDC25A transcript is 3704 bp in length. So far 
two major transcript variant have been reported, 
CDC25A1 and A2.  
The transcript variant CDC25A2, has a deletion of 
120 nucleotides (exon 6) resulting in a protein 
having truncation of 40 amino acids (between amino 
acid 160-201).  
However, both the N-terminal and C-terminal end of 
the protein is the same in both splice variant. 
Protein 
Description 
The full length CDC25A protein consists of 524 
amino acids with an estimated molecular weight of 
59 kDa.  
The other reported isoform CDC25A2, consists of 
484 amino acids with a molecular weight of 54.4 
kDa (Wegener et al., 2000).. Both the isoforms have 
the same N- and C-terminal end, thus expected to 
have similar catalytic activity.  
The N-terminal regulatory domain contains several 
phosphorylation sites and shows low sequence 
homology between CDC25 family members, 
whereas C-terminal end has conserved Rhodanese 
homology domain containing the active site 
cysteine.  
The catalytic site contain the CX5R motif (C= 
cysteine; X= any amino acid; R= arginine) common 
to all protein tyrosine phosphatases (Boutros et al., 
2006).  
Upon apoptosis induction, CDC25A is cleaved at 
D223 (D=Aspartic acid) by caspase to generate a 
catalytically active CDC25A C-terminal 37Kda 
protein (Mazars et al., 2009; Chou et al., 2010). 
Expression 
CDC25A is expressed early during embryonic stages 
and in adults it is expressed in a variety of normal 
cells and tissues.  
CDC25A is a highly expressed gene in a variety of 
human cancers including breast, esophageal, gastric, 
lung, thyroid, head and neck cancers and also in high 
grade lymphomas. 
Localisation 
CDC25A initially believed to be a nuclear protein. 
But using fluorescence loss in photobleaching 
(FLIP) a more dynamic nuclear-cytosolic shuttling 
of CDC25A localization has been reported.  
At the very N-terminus end between amino acid 38-
59, the nuclear export sequence (NES) is located, 
whereas between amino acid 272-294, a bipartite 
nuclear localization signal (NLS) was proved to be 
important for its nuclear localization (Källström et 
al., 2005).  
Depending of the cell line, CDC25A is nuclear or 
nuclear and cytoplasmic. 
Function 
- CDC25A is essential for early embryonic 
development as Cdc25A-null mice die in utero by 
embryonic day 7(Ray et al., 2007). 
- It is a member of the M-phase inducer (MPI) 
phosphatase family protein, which not only regulates 
mitotic progression by activating mitotic CDKs in a 
dosage-dependent manner, it is also equally 
important in G1 and for G1 to S-phase transition. 
- During G1, CDC25A dephosphorylates 
CDK4/CDK6 on tyrosine 17 and 24, respectively, 
allowing their association with D-type cyclins and 
thus their activation (Bertero et al., 2013). During G1 
to S transition, it activates CDK2 by removing two 
inhibitory phosphates on residues threonine 14 and 
tyrosine 15. During G2/M transition CDC25A 
similarly regulates the activity of CDK1 (CDC2). 
- It is an inhibitor of apoptosis by inhibiting 
apoptosis signal-regulating kinase 1 (ASK1). in a 
phosphatase-independent manner, by activating the 
AKT-survival pathway in the cytoplasm and also by 
stimulating NF-kB activity through NFKBIA (IκB- 
α) destabilization (review Fernandez-Vidal et al., 
2008; review Shen and Huang, 2012; Hong et al., 
2012). But overexpressed nuclear CDC25A also 
exhibits pro apoptotic activity by activating the pro-
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apoptotic factor FKHLR1 (review Fernandez-Vidal 
et al., 2008; review Shen and Huang, 2012). 
- CDC25A plays an important role in 
spermatogenesis as decreased transcript level of 
Cdc25A is correlated with spermatogenic failure and 
failed sperm retrieval in infertile men. (Cheng et al., 
2009). 
-CDC25A also plays a role in meiotic maturation of 
oocytes, its activity is required for the metaphase II 
arrest in mouse oocytes (Oh et al., 2013). 
- CDC25A was shown to function as a androgen 
receptor corepressor in prostate cancer cells (Chiu et 
al., 2009). 
Regulation 
- CDC25A is transcriptionally regulated by E2F, a 
transcription factor implicated at the G1/S transition, 
c-myc, STAT3, the p53-pathway via the 
transcription factor ATF3, TCF/beta-catenin, 
FOXM1, NANOG in embryonic stem cell and 
PROX1 in neural precursor (review Fernandez-
Vidal et al., 2008; review Shen and Huang, 2012). 
- CDC25A is also regulated at the translational level 
by the translation initiation factors EIF2S1 
(eIF2alpha), EIF3M, the RNA-binding proteins 
BOLL in spermatogenesis, and various miRNAs 
such as let7b, 15a, 21, 449a, 449b, 483-3p, 424/503 
cluster and 141-3p. Some of these miRNAs being 
deregulated in cancers can contribute to the 
overexpression of CDC25A in cancers. 
- CDC25A activity can be regulated by  
phosphorylation events (review Fernandez-Vidal et 
al., 2008; review Shen and Huang, 2012). The 
kinases PIM-1, RAF1, CDK2, RSK, ROCK1 
(p160Rock) and the phosphatase CDC14B have 
been shown to regulate CDC25A activity. The 
kinase CHK1 has been shown to phosphorylate 
CDC25A on serine 178 and threonine 507 
preventing its interaction with its CDK/cyclin 
substrates. 
- CDC25A is an unstable protein in interphase, or 
under several different stress conditions (DNA 
damage induced by ionizing radiation, ultraviolet 
light, replicative stress) being degraded by the 
proteasome after ubiquitination by SCFβTrCP E3 
ubiquitin ligase. This ubiquitination is dependent on 
several phosphorylation events in the N-terminal 
part of the protein carried out by many kinases such 
as CHK1 (on serine 76, 124, 178, 279 and 293), 
CHK2 (on serine 124, 178 and 293), p38MAPK (on 
serine 76), GSK3-β (on serine 76), Plk3 (on 
threonine 80), NEK11 (on serine 82 and 88) and 
CK1alpha and epsilon (on serine 82) (review 
Fernandez-Vidal et al., 2008; review Shen and 
Huang, 2012). 
- CDC25A protein is stabilized during mitosis due to 
phosphorylation on serine 18 and 116 by 
CDK1/cyclinB occuring at the G2/M transition 
(Mailand et al., 2002). At the mitotic exit and in early 
G1, CDC25A is degraded by the proteasome after 
ubiquitination by the E3 ubiquitine ligase APC/C 
(cyclosome) (review Fernandez-Vidal et al., 2008; 
review Shen and Huang, 2012). 
- CDC25A protein level is important for oncogene-
induced transformation and mouse mammary tumor 
virus (MMTV)-neu/ras induced mammary 
tumorigenesis (Ray et al., 2007). 
- During early cell cycle progression glycogen 
synthase kinase 3-beta (GSK-3β) can phosphorylate 
allowing its proteasomal degradation. Interestingly, 
the same report showed that overproduction of 
CDC25A in some human cancers is correlated to the 
inactivation of GSK-3β (Kang et al., 2008). 
- Overexpression of CDC25A in some human 
sarcomas has also been shown to be the result of 
transcriptional upregulation involving the 
transcription factor TCF/β-catenin upregulated upon 
activation of the wnt canonical signaling 
(Vijayakumar et al.,2011). HOMOLOGY CDC25A 
gene is highly conserved among mammals (99% 
homology with Chimpanzee; 90% with dog; about 
86% with rat and about 85% with mouse). In 
mammals, CDC25A has two orthologs, CDC25B 
and CDC25C. Among them, the N-terminal 
regulatory region show low sequence homology (20-
25% identity), however, the C-terminal catalytic 
region is quite conserved with about 64% homology 
with CDC25B and about 58% homology to 
CDC25C. 
Mutations 
Gene mutation or amplification is not commonly 
reported for CDC25A. A naturally occurring point 
mutation (C to A) of mouse Cdc25A gene has been 
reported where Histidine 128 (CAC) has been 
converted to Glutamine (CAA). This change caused 
an increase in CDC25A phosphatase activity and 
thereby affected erythropoiesis in mice only under 
certain genetic background  (Melkun et al., 2002). A 
human polymorphism variant in which Serine 88 is 
converted to Phenylalanine has been described. This 
variant fails to interact with ASK1 and therefore 
does not suppress ASK1-mediated apoptosis, which 
leads to early embryonic lethality in mice and 




- CDC25A is overexpressed in a variety of human 
cancers including breast, hepatocellular, ovarian, 
colorectal, gastric, lung, thyroid, esophageal, 
laryngeal, head and neck cancers, retinoblastoma, 
glioma,  and also in non-Hodgkin lymphoma. often 
associated with high grade tumours and bad 
prognosis (Boutros et al., 2007).  
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- Upregulation of CDC25A is also observed down-
stream of the NPM1 / ALK oncogene in anaplastic 
large cell lymphoma and participates to their 
enhanced proliferation (Fernandez-Vidal et al., 
2009). 
- CDC25A is overexpressed in erythroleukemia cell 
lines expressing the JAK2V617F oncogene, present 
in the majority of patients with polycythemia vera 
and one-half of those with essential 
thrombocythemia and primary myelofibrosis. This 
upregulation occurs at the translational level through 
the transcription factor STAT5 and the translational 
initiation factor eIF2alpha (Gautier et al., 2012).  
- An upregulation of CDC25A activity due to its 
phosphorylation by deregulated CDK5 has been 
observed in Alzheimer's disease (Chang et al., 2012). 
Breast cancer 
Note 
- In about 47% of early (T1) stage breast cancer 
patients CDC25A is reported to be overexpressed. 
- In some breast cancer cell lines it was reported that 
CDC25A overexpression is mainly due to increased 
protein stability as oppose to gene amplification or 
transcriptional upregulation. (Löffler et al., 2003). In 
a subset of human breast cancers overexpression of 
the ubiquitin hydrolase DUB3, which 
deubiquitinates CDC25A preventing its degradation, 
is shown to be responsible for overexpression of 
CDC25A (Pereg et al., 2010).  
- In mice, overexpression of CDC25A alone in 
mammary gland using mouse mammary tumor virus 
(MMTV) promoter, is not sufficient to induce 
mammary tumorigenesis. However, such mammary 
specific overexpression of CDC25A does cooperate 
with HER2/neu-ras signaling to form more 
aggressive tumors with enhanced genomic 
instability. (Ray et al., 2007).  
- In contrast, hemizygous loss of Cdc25A in mice 
protected them significantly from MMTV-neu/ras-
induced mammary tumorigenesis, possibly by 
restricting precancerous cell proliferation and also 
by enhancing G2-checkpoint response. Thus the 
protein level of CDC25A is crucial for the initiation 
and/or progression of breast tumorigenesis in mice 
(Ray and Kiyokawa, 2007). 
Prognosis 
Overexpression of CDC25A is correlated with more 
aggressive breast cancer with poor prognosis. 
Cytogenetics 
CDC25A overexpression in MMTV-CDC25A; 
MMTV-neu double transgenic mice caused faster 
tumor growth as compared to MMTV-neu single 
transgenic mice. Importantly, such CDC25A 
overexpressing tumor cells displayed  
miscoordination of S phase and mitosis, and had 
severe genomic instability as evidenced by 
aneuploidy and deletion of fragile chromosomal 
regions (e.g., telomeric region of chromosome 4, 
which is homologous to human chromosome 1p31-




Overexpression of CDC25A mRNAs was found in 
69% of hepatocellular carcinomas (HCCs) and this 
overexpression was also confirmed by 
Immunohistochemistry (56% HCCs exhibit 
overexpression of CDC25A) and western blot 
analysis (Xu et al., 2003). Different CDC25 inhibitor 
(such as vitamin K analog Cpd 5; phenyl maleimide 
compound PM-20; 2-Methoxyestadiol, a 
physiological metabolite of estrogen) are capable of 
inhibiting the hepatocellular carcinoma growth both 
in vitro and in vivo (Wang et al., 2001; Kar et al, 
2006). 
Disease 
High expression of CDC25A was associated with 
dedifferentiated phenotype and portal vein invasion. 
Prognosis 
CDC25A overexpression is associated with poor 
prognosis of hepatocellular carcinoma. 
Retinoblastoma 
Note 
Overexpression of CDC25A mRNAs was found in 
48,33 % retinoblastomas, confirmed by 
immunohistochemistry (52,29 %) and western 
blotting  (Shingh et al., 2014). 
Prognosis 
Expression of CDC25A showed significant 




High level of CDC25A mRNAs was found in 35 % 
of the tumors and were more frequently observed in 
aggressive than in indolent lymphomas. This was 
also confirmed at the protein level. 
Gastric cancer 
Note 
By immunohistochemistry CDC25A was found 
expressed in 87.1 % of gastric carcinomas, 
correlated with c-myc overexpression (Xing et al., 
2008). 
Disease 
Overexpression of CDC25A was independent of 
intestinal or diffuse type of gastric cancer. 
 
Prognosis 
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Association between CDC25A expression and 
higher histological grade of differentiation. 
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